AQST
The setup: all systems go... until they weren’t
According to the complaint, Aquestive Therapeutics spent much of the class period telling investors that Anaphylm was cruising toward FDA approval by the January 31, 2026 PDUFA date. Management allegedly painted the review as routine, said commercial launch prep was already underway for Q1 2026, and generally gave off “nothing to see here” energy.
Then the FDA mood changed
The lawsuit says that story broke down fast. After the company’s November 6, 2025 earnings call — where management said the FDA was basically doing its checklist homework — regulators allegedly flagged enough issues to stop labeling discussions cold. That’s the kind of plot twist investors hate: the company’s confidence meter was high, but the regulator apparently did not get the memo.
Why investors should care
If the allegations stick, this isn’t just a legal headache. It can also raise questions about disclosure, credibility, and how much faith investors should put in the company’s future timelines. For a small biotech with a lot riding on one asset, that can matter more than the headline itself.
Big picture
Biotech stocks can move on the promise of a clean FDA runway — and they can get punished just as quickly when that runway turns out to be a pothole-filled side street. The lawsuit won’t decide the drug’s fate, but it could keep pressure on AQST while the market waits for more clarity.